Biote (BTMD) Stock News

biote (Nasdaq: BTMD) will release first quarter 2026 financial results on Wednesday, May 6, 2026 after market close and will host a conference call the same day at 5:00 p.m. ET.

Investors may dial U.S. and international numbers or join a live webcast; a replay will be posted on the company’s Investor Relations Events page shortly after the call.

Biote (NASDAQ: BTMD) reported Q4 2025 revenue of $46.4M and full-year 2025 revenue of $192.2M. Q4 procedure revenue fell 13.0% while dietary supplements grew 16.0%. 2025 net income was $31.6M with diluted EPS of $0.74. 2026 guidance: revenue above $190M and Adjusted EBITDA above $38M, with an expected H1 2026 procedure revenue decline and return to growth in H2 2026.

biote Corp. (Nasdaq: BTMD) will release fourth quarter and full year 2025 financial results on Wednesday, March 11, 2026 after market close.

A conference call to discuss results is scheduled the same day at 5:00 p.m. ET. According to the company, the call can be accessed by dialing the provided U.S. and international numbers or via a live webcast; a replay will be posted on the investor events page.

Biote (NASDAQ: BTMD) reported third quarter 2025 results with revenue of $48.0M (down 6.7% YoY), gross margin 71.8%, net income of $9.2M and diluted EPS of $0.22. Procedure revenue fell 10.4% while dietary supplements grew 8.4%. Adjusted EBITDA was $12.9M with a 26.9% margin. The company repurchased ~1 million Class A shares and completed share repurchase payments to settle legacy earnout obligations totaling $12.5M and an agreed $18.5M payment due Jan 2026. Biote reiterated 2025 guidance: revenue above $190M and Adjusted EBITDA above $50M.

biote (Nasdaq: BTMD) will release Q3 2025 financial results on Wednesday, November 5, 2025 after market close. A conference call to discuss results is scheduled the same day at 5:00 p.m. ET.

Investors can access the call by dialing (844) 481-2820 (U.S. toll-free) or (412) 317-0679 (international) or via the live webcast. A replay of the webcast will be posted on the Events page of the biote investor relations website shortly after the event concludes.

Biote (NASDAQ: BTMD), a preventive healthcare company specializing in hormone optimization, reported Q2 2025 financial results with revenue of $48.9 million, slightly down from $49.2 million year-over-year. The company achieved a gross profit margin of 71.6% and net income of $3.9 million ($0.10 per diluted share).

Key highlights include a 30.4% increase in dietary supplement revenue, though procedure revenue declined 8.4%. Adjusted EBITDA grew 19.1% to $15.2 million, with margin expanding to 31.1%. The company initiated an organizational restructuring in May 2025 and revised its fiscal 2025 guidance downward to revenue above $190 million and Adjusted EBITDA above $50 million, compared to previous guidance of $202-208 million and $59-64 million respectively.

Biote (NASDAQ:BTMD), a provider of personalized hormone optimization and therapeutic wellness solutions, has scheduled its second quarter 2025 financial results release for Wednesday, August 6, 2025, after market close.

The company will host a conference call at 5:00 p.m. ET the same day. Investors can access the call by dialing (844) 481-2820 (U.S. toll-free) or (412) 317-0679 (International). A webcast replay will be available on Biote's Investor Relations website after the event.

Biote Corp (NASDAQ: BTMD), a provider of personalized hormone optimization and therapeutic wellness solutions, has appointed Rich Barrera to its Board of Directors. Barrera, who is the Founder and CEO of Roystone Capital, brings over 20 years of investment management experience to the role. His firm Roystone Capital is one of Biote's major institutional shareholders. Prior to founding Roystone in 2012, Barrera held positions at Redwood Capital Management and Glenview Capital Management. He previously served as Chair of the Finance Committee at Pacific Gas & Electric and holds an MBA from Harvard Business School and a BS in Accounting and Finance from the Wharton School.

Biote (BTMD) reported strong Q1 2025 financial results with revenue of $49.0 million, up 4.7% year-over-year. The company achieved a net income of $15.8 million and diluted EPS of $0.37, compared to a net loss in the previous year. Gross profit margin improved to 74.3%, primarily due to vertical integration of their 503B manufacturing facility. While dietary supplements revenue increased 25.5%, procedure revenue decreased 3.6%. The company announced a strategic restructuring to enhance sales force productivity, including a 25% increase in sales representatives through internal reorganization. Biote maintained its 2025 guidance with expected revenue of $202-208 million and Adjusted EBITDA of $59-64 million. The restructuring will incur charges of $0.6-0.8 million in Q2 2025.